WST - West Pharmaceutical Services, Inc.
After hours:
| Previous close | 341.53 |
| Open | 342.69 |
| Bid | 333.00 x 800 |
| Ask | 350.90 x 800 |
| Day's range | 340.21 - 343.93 |
| 52-week range | 206.19 - 376.72 |
| Volume | |
| Avg. volume | 443,579 |
| Market cap | 25.519B |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | 46.96 |
| EPS (TTM) | 7.32 |
| Earnings date | 26 Jul 2023 - 31 Jul 2023 |
| Forward dividend & yield | 0.76 (0.22%) |
| Ex-dividend date | 25 Jul 2023 |
| 1y target est | 369.22 |
ZacksCooper Companies (COO) Q2 Earnings and Revenues Beat Estimates
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
ZacksStryker's (SYK) Q Guidance Successful in First Surgery
Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.
ZacksAbbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
- Zacks
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
ZacksHere's Why Investors Should Retain STERIS (STE) Stock for Now
Investors are optimistic about STERIS (STE) on strong segmental growth.
ZacksHere's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Simply Wall St.Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
West Pharmaceutical Services' (NYSE:WST) stock is up by a considerable 35% over the past three months. Since the market...
ZacksWest Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong
West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
ZacksWest Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.56% and 2.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksZacks Industry Outlook Highlights West Pharmaceutical Services, The Cooper Companies and Henry Schein
West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.
ZacksWest Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy?
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksMedical Device Stocks' Q1 Earnings on Apr 27: WST, DXCM, BAX
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
Zacks3 Dental Supplies Stocks to Buy as Industry Prospects Recover
Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.
ZacksHenry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksLabCorp (LH) Misses Q1 Earnings Estimates
LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
What's in Store for West Pharmaceutical (WST) in Q1 Earnings?
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
ZacksBDX vs. WST: Which Stock Is the Better Value Option?
BDX vs. WST: Which Stock Is the Better Value Option?
- Simply Wall St.
West Pharmaceutical Services' (NYSE:WST) investors will be pleased with their solid 296% return over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
ZacksBDX or WST: Which Is the Better Value Stock Right Now?
BDX vs. WST: Which Stock Is the Better Value Option?
ZacksMerit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It Rebound?
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
- Simply Wall St.
Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Today we're going to take a look at the well-established West Pharmaceutical Services, Inc. ( NYSE:WST ). The company's...
ZacksHSIC or WST: Which Is the Better Value Stock Right Now?
HSIC vs. WST: Which Stock Is the Better Value Option?
ZacksMMSI vs. WST: Which Stock Is the Better Value Option?
MMSI vs. WST: Which Stock Is the Better Value Option?
- Simply Wall St.
West Pharmaceutical Services Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
West Pharmaceutical Services ( NYSE:WST ) Full Year 2022 Results Key Financial Results Revenue: US$2.89b (up 2.0% from...